Abstracts tagged "Biomarkers and takayasu arteritis"

Abstract Number: 3055 • 2015 ACR/ARHP Annual Meeting
Evaluation of Plasma Pentraxin-3 Level in Patients with Takayasu’s Arteritis
Fatma Alibaz-Oner^1,2, Kenan Aksu³, P.Sibel Yentür⁴, Gokhan Keser⁵, Guher Saruhan-Direskeneli⁶ and Haner Direskeneli⁷, ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ³Dept. Of Internal Medicine, Division of Rheumatology, Ege University, Dept. Of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, ⁴Physiology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey, ⁵Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ⁶Department of Physiology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁷Rheumatology, Marmara University, Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Assessment of disease activity is one of the major difficulties in patients with TAK during follow-up. To date, no biomarker is universally accepted to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].